Longs Peak Hospital
Longs Peak Hospital was paid $11.87M by Medicaid between Jan 2018 and Dec 2024, across 107 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 22% of everything it billed.
LONGMONT, CO 80504
Next to other General Acute Care Hospital providers in Colorado
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,935 | $403K | |
| 2019 | 13,991 | $638K | |
| 2020 | 25,066 | $938K | |
| 2021 | 51,924 | $1.92M | |
| 2022 | 53,880 | $2.83M | |
| 2023 | 45,690 | $2.98M | |
| 2024incomplete | 28,909 | $2.16M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 22% | 8,609 | 7,934 | $2.56M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 19,346 | 17,811 | $2.50M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 14,596 | 13,776 | $1.95M |
| 90870 | 16% | 4,235 | 1,352 | $1.85M | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 11,117 | 10,432 | $1.47M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.1% | 8,552 | 7,341 | $487K |
| 80053 | Comprehensive metabolic panel | 1.5% | 15,033 | 13,771 | $177K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.4% | 2,160 | 2,048 | $162K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.1% | 6,793 | 5,775 | $136K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 244 | 233 | $94K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,450 | 1,394 | $76K |
| 0001A | <1% | 622 | 602 | $56K |
95 more codes
| 0002A | <1% | 542 | $49K | |
| 84484 | <1% | 1,624 | $37K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 175 | $36K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,892 | $33K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 486 | $27K |
| 86850 | <1% | 497 | $18K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 567 | $17K |
| 88342 | <1% | 460 | $15K | |
| 0012A | <1% | 147 | $12K | |
| 80306 | <1% | 448 | $11K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 486 | $10K |
| 86787 | <1% | 540 | $8K | |
| 86769 | <1% | 178 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 89 | $6K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 528 | $5K |
| 87340 | <1% | 508 | $5K | |
| 86803 | <1% | 197 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,078 | $3K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 14 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,802 | $3K |
| 86762 | <1% | 164 | $3K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 14 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 15 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,732 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,953 | $3K |
| 86900 | <1% | 526 | $2K | |
| J3490 | Unclassified drugs | <1% | 28,840 | $2K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12 | $2K |
| 86765 | <1% | 180 | $2K | |
| 86735 | <1% | 181 | $2K | |
| 95806 | <1% | 12 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,330 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,491 | $1K |
| 82043 | <1% | 13 | $1K | |
| 86901 | <1% | 526 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 26 | $1K |
| J7999 | Compounded drug, not otherwise classified | <1% | 4,062 | $897.47 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 50 | $837.71 |
| 87510 | <1% | 12 | $769.12 | |
| 82570 | <1% | 27 | $753.62 | |
| 83605 | <1% | 15 | $687.15 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 17 | $670.34 |
| 94060 | <1% | 14 | $527.88 | |
| 87081 | <1% | 13 | $498.07 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 13 | $440.10 |
| 87480 | <1% | 12 | $423.34 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,340 | $407.25 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 37 | $398.66 |
| 82607 | <1% | 51 | $394.48 | |
| 82746 | <1% | 38 | $385.65 | |
| 87660 | <1% | 12 | $384.56 | |
| 94729 | <1% | 15 | $307.30 | |
| 0352U | <1% | 12 | $262.46 | |
| 83540 | <1% | 50 | $193.40 | |
| 82728 | <1% | 38 | $188.83 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 13 | $158.00 |
| 86140 | <1% | 66 | $156.80 | |
| 83690 | <1% | 4,039 | $136.11 | |
| 84466 | <1% | 50 | $136.05 | |
| 86780 | <1% | 14 | $101.93 | |
| 80061 | Lipid panel | <1% | 25 | $99.09 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 25 | $91.52 |
| 86160 | <1% | 13 | $90.40 | |
| 85027 | <1% | 767 | $84.33 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 12 | $76.74 |
| 86364 | <1% | 12 | $49.32 | |
| 84703 | <1% | 539 | $42.96 | |
| 82077 | <1% | 87 | $38.40 | |
| Q3014 | Telehealth originating site facility fee | <1% | 52 | $28.65 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13 | $24.94 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,527 | $13.60 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,052 | $9.63 |
| 81001 | <1% | 2,524 | $2.22 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,151 | $2.04 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,916 | $0.11 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,868 | $0.04 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 919 | $0.03 |
| 83735 | 0% | 375 | $0.00 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 1,391 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 18 | $0.00 |
| 83880 | 0% | 13 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 15 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 16 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 15 | $0.00 |
| 96376 | 0% | 12 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 42 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 17 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 20 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 167 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 137 | $0.00 |
| 71046 | Radiologic examination, chest; 2 views | 0% | 30 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 135 | $0.00 |
| 81025 | 0% | 97 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 75 | $0.00 |
| 81003 | 0% | 278 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| University of Colorado Hospital Authority | Denver, CO | $3.23M |
| Uchealth Broomfield Hospital | Broomfield, CO | $1.01M |
| Uchealth Highlands Ranch Hospital | Highlands Ranch, CO | $655K |
| University of Colorado Hospital Authority | Aurora, CO | $535K |
| University of Colorado Hospital Authority | Aurora, CO | $476K |
| University of Colorado Hospital Authority | Aurora, CO | $233K |
| University of Colorado Hospital Authority | Aurora, CO | $158K |
| University of Colorado Hospital Authority | Aurora, CO | $47K |
| University of Colorado Hospital Authority | Denver, CO | $30K |
| University of Colorado Hospital Authority | Aurora, CO | $14K |
| Uchealth Broomfield Hospital | Broomfield, CO | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.